COVID 19 rapid evidence summary: Anakinra for COVID-19 associated secondary haemophagocytic lymphohistiocytosis, NICE [26]

" Anakinra is a recombinant interleukin-1 (IL-1) receptor antagonist that blocks the biologic activity of natural IL-1 by competitively inhibiting the binding of IL-1 to the interleukin-1 type receptor (Kineret summary of product characteristics). IL-1 is a proinflammatory mediator produced in response to infection and is central to the hyperinflammation seen in cytokine storm syndromes such as sHLH (Mehta et al 2020). "
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news